VivoSeq
Psychiatry

Drug Dependence

51

Pipeline Programs

0

Active Trials

32

Companies Involved

Drug Dependence is a moderately active landscape with 51 programs across 32 companies. The most active players are Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Lykos Therapeutics, Eisai. 42 therapies are approved.

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

50/100

Attrition Rate

50/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

98%

Small molecule

52 of 53 classified programs — the dominant modality here.

2%ALL OTHERSPeptide12%

Small molecule leads; the ring shows all 53 classified programs, each share of the total. Modality classified for 100% of 53 pipeline programs.

Trial Status

2

clinical trials

Terminated1 · 50%
Completed1 · 50%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)